Literature DB >> 15087584

Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies.

Ian G McKeith1, Keith A Wesnes, Elaine Perry, Roberto Ferrara.   

Abstract

The aim of this analysis of the effects of cholinergic therapy in dementia with Lewy bodies was to determine whether rivastigmine-induced benefits in attention and memory could be predicted by the presence of visual hallucinations. At study entry, 74% of patients were hallucinators and 26% were non-hallucinators. The population was analyzed for two-factor scores: power of attention (PoA) and quality of memory (QoM). A significant effect over placebo on PoA was observed in hallucinators at weeks 12 (p = 0.023) and 20 (p = 0.0019), while no treatment effects were seen in non-hallucinators. Significant treatment effects on QoM were not observed in either subgroup. Visual hallucinations predicted greater improvements in PoA, but not QoM. This may reflect the greater cholinergic deficits in areas of the brain responsible for visual hallucinations, offering greater potential for attentional improvement. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15087584     DOI: 10.1159/000077816

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  10 in total

Review 1.  Visual spatial cognition in neurodegenerative disease.

Authors:  Katherine L Possin
Journal:  Neurocase       Date:  2010-06-02       Impact factor: 0.881

Review 2.  Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.

Authors:  Daniel Weintraub; Howard I Hurtig
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

Review 3.  Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management.

Authors:  Dag Aarsland; Sally Sharp; Clive Ballard
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 4.  Update on dementia with Lewy bodies.

Authors:  David J Burn
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 5.  Treatment of dementia with Lewy bodies and Parkinson's disease dementia.

Authors:  Clive Ballard; Zunera Kahn; Anne Corbett
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

6.  Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.

Authors:  Howard H Feldman; Roger Lane
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-12       Impact factor: 10.154

7.  Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review.

Authors:  Federico Emanuele Pozzi; Elisa Conti; Ildebrando Appollonio; Carlo Ferrarese; Lucio Tremolizzo
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

8.  Dementia with Lewy bodies.

Authors:  Ian McKeith
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

9.  Cholinergic and perfusion brain networks in Parkinson disease dementia.

Authors:  Sean J Colloby; Ian G McKeith; David J Burn; David J Wyper; John T O'Brien; John-Paul Taylor
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

10.  Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.

Authors:  Ying Jiang; John J Alam; Stephen N Gomperts; Paul Maruff; Afina W Lemstra; Ursula A Germann; Philip H Stavrides; Sandipkumar Darji; Sandeep Malampati; James Peddy; Cynthia Bleiwas; Monika Pawlik; Anna Pensalfini; Dun-Sheng Yang; Shivakumar Subbanna; Balapal S Basavarajappa; John F Smiley; Amanda Gardner; Kelly Blackburn; Hui-May Chu; Niels D Prins; Charlotte E Teunissen; John E Harrison; Philip Scheltens; Ralph A Nixon
Journal:  Nat Commun       Date:  2022-09-21       Impact factor: 17.694

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.